{"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/35212828","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85125283470&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=385453","label":"url"}],"paper_title":{"en":"Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy","ja":"Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy"},"authors":{"en":[{"name":"Abe Akiko"},{"name":"Yuasa Masao"},{"name":"Imai Yoshie"},{"name":"Kagawa Tomohiro"},{"name":"Mineda Ayuka"},{"name":"Nishimura Masato"},{"name":"Tonoiso Chisato"},{"name":"Kubo Akiko"},{"name":"Kawanaka Takashi"},{"name":"Ikushima Hitoshi"},{"name":"Iwasa Takeshi"}],"ja":[{"name":"阿部 彰子"},{"name":"Yuasa Masao"},{"name":"今井 芳枝"},{"name":"香川 智洋"},{"name":"峯田 あゆか"},{"name":"西村 正人"},{"name":"外礒 千智"},{"name":"久保 亜貴子"},{"name":"川中 崇"},{"name":"生島 仁史"},{"name":"岩佐 武"}]},"description":{"en":"Human papillomavirus vaccination is not widespread in Japan, and the low screening rates result in many cases of locally advanced cervical cancer. We investigated the prognostic significance of sarcopenia in patients with cervical cancer to guide healthcare policies to improve treatment outcomes. This retrospective study included 83 patients with cervical cancer without distant metastasis who underwent primary concurrent chemoradiotherapy between 2013 and 2018. We analyzed the indicators of physical condition and muscle quantity using the SYNAPSE VINCENT software. Muscle mass and the relationship between treatment toxicity and prognosis were evaluated. The patients' median age was 60 (range 33-80) years. Cancer stage distribution was as follows: cT2b or higher, 84.3%; N1, 65.1%; and MA, 27.7%. The overall sarcopenia (skeletal muscle index [SMI] < 38.5) rate was 30.1%, and the rate was 33.9 and 22.2% in patients aged < 64 and ≥ 65 years, respectively. No correlation was observed between clinical stage and musculoskeletal indices. Treatment resulted in decreased body weight and SMI; after treatment, the sarcopenia rate increased to 37.3%. A higher intramuscular adipose tissue content (IMAC) reduced the number of chemotherapy cycles needed. Treatment-associated SMI decreases of ≥ 7% indicated poor prognosis, with significant differences in progression-free survival and overall survival (p = 0.013 and p = 0.012, respectively). Patients who were very lean (body mass index < 18.5 kg/m) before treatment had a poor prognosis (p = 0.016 and p < 0.001). Our findings emphasize the importance of assessing original nutritional status and maintaining muscle mass and quality during the treatment of patients with cervical cancer.","ja":"Human papillomavirus vaccination is not widespread in Japan, and the low screening rates result in many cases of locally advanced cervical cancer. We investigated the prognostic significance of sarcopenia in patients with cervical cancer to guide healthcare policies to improve treatment outcomes. This retrospective study included 83 patients with cervical cancer without distant metastasis who underwent primary concurrent chemoradiotherapy between 2013 and 2018. We analyzed the indicators of physical condition and muscle quantity using the SYNAPSE VINCENT software. Muscle mass and the relationship between treatment toxicity and prognosis were evaluated. The patients' median age was 60 (range 33-80) years. Cancer stage distribution was as follows: cT2b or higher, 84.3%; N1, 65.1%; and MA, 27.7%. The overall sarcopenia (skeletal muscle index [SMI] < 38.5) rate was 30.1%, and the rate was 33.9 and 22.2% in patients aged < 64 and ≥ 65 years, respectively. No correlation was observed between clinical stage and musculoskeletal indices. Treatment resulted in decreased body weight and SMI; after treatment, the sarcopenia rate increased to 37.3%. A higher intramuscular adipose tissue content (IMAC) reduced the number of chemotherapy cycles needed. Treatment-associated SMI decreases of ≥ 7% indicated poor prognosis, with significant differences in progression-free survival and overall survival (p = 0.013 and p = 0.012, respectively). Patients who were very lean (body mass index < 18.5 kg/m) before treatment had a poor prognosis (p = 0.016 and p < 0.001). Our findings emphasize the importance of assessing original nutritional status and maintaining muscle mass and quality during the treatment of patients with cervical cancer."},"publication_date":"2022-03","publication_name":{"en":"International Journal of Clinical Oncology","ja":"International Journal of Clinical Oncology"},"volume":"Vol.27","number":"No.5","starting_page":"983","ending_page":"991","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s10147-022-02140-w"],"issn":["1437-7772"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/31640461","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378948","label":"url"}],"paper_title":{"en":"Clinical and biological significance of expression in endometrial cancer.","ja":"Clinical and biological significance of expression in endometrial cancer."},"authors":{"en":[{"name":"Roh Ju-Won"},{"name":"Choi Eun Jung"},{"name":"Han Dong Hee"},{"name":"Hu Wei"},{"name":"Matsuo Koji"},{"name":"Nishimura Masato"},{"name":"Lee Ju-Seog"},{"name":"Kwon Young Sun"},{"name":"Cho Heum Chi"},{"name":"Kim Jongseung"},{"name":"Coleman L. Robert"},{"name":"Lopez-Bernstein Gabriel"},{"name":"Sood K. Anil"}],"ja":[{"name":"Roh Ju-Won"},{"name":"Choi Eun Jung"},{"name":"Han Dong Hee"},{"name":"Hu Wei"},{"name":"Matsuo Koji"},{"name":"西村 正人"},{"name":"Lee Ju-Seog"},{"name":"Kwon Young Sun"},{"name":"Cho Heum Chi"},{"name":"Kim Jongseung"},{"name":"Coleman L. Robert"},{"name":"Lopez-Bernstein Gabriel"},{"name":"Sood K. Anil"}]},"description":{"en":"The objective of this study was to examine the clinical significance of expression and the therapeutic efficacy of its silencing in endometrial cancer. expression in clinical samples was evaluated using a tissue microarray and correlated with clinical outcomes. The biological roles of EZH2 were assayed and . Gene expression was examined to reveal the molecular mechanism underlying the roles of EZH2 in endometrial cancer. We found that overexpression was significantly correlated with disease-free and overall survival of patients with endometrial cancer. silencing resulted in decreased cell viability and invasiveness, and increased apoptosis. In addition, silencing enhanced the cytotoxicity of taxanes and cisplatin in Hec-1A and Ishikawa endometrial cancer cells. silencing using small-interfering RNA (siRNA) incorporated into chitosan nanoparticles (siRNA/CN) induced a significant anti-tumor effect compared with that observed in controls (66.6% reduction in Hec-1A cells and 63.2% reduction in Ishikawa cells, < .05 for both). Moreover, siRNA/CN in combination with taxanes produced more robust anti-tumor effects versus those induced by monotherapies (77.0% for Hec-1A cells and 57.7% for Ishikawa cells, < .05 for both). These results were associated with decreased angiogenesis and cell proliferation, and enhanced apoptosis. Genomic analyses revealed that silencing decreased the expression levels of many genes associated with tumor growth, including . Collectively, these results support as an attractive target for the therapeutic management of endometrial cancer.","ja":"The objective of this study was to examine the clinical significance of expression and the therapeutic efficacy of its silencing in endometrial cancer. expression in clinical samples was evaluated using a tissue microarray and correlated with clinical outcomes. The biological roles of EZH2 were assayed and . Gene expression was examined to reveal the molecular mechanism underlying the roles of EZH2 in endometrial cancer. We found that overexpression was significantly correlated with disease-free and overall survival of patients with endometrial cancer. silencing resulted in decreased cell viability and invasiveness, and increased apoptosis. In addition, silencing enhanced the cytotoxicity of taxanes and cisplatin in Hec-1A and Ishikawa endometrial cancer cells. silencing using small-interfering RNA (siRNA) incorporated into chitosan nanoparticles (siRNA/CN) induced a significant anti-tumor effect compared with that observed in controls (66.6% reduction in Hec-1A cells and 63.2% reduction in Ishikawa cells, < .05 for both). Moreover, siRNA/CN in combination with taxanes produced more robust anti-tumor effects versus those induced by monotherapies (77.0% for Hec-1A cells and 57.7% for Ishikawa cells, < .05 for both). These results were associated with decreased angiogenesis and cell proliferation, and enhanced apoptosis. Genomic analyses revealed that silencing decreased the expression levels of many genes associated with tumor growth, including . Collectively, these results support as an attractive target for the therapeutic management of endometrial cancer."},"publication_date":"2020-02","publication_name":{"en":"Cancer Biology & Therapy","ja":"Cancer Biology & Therapy"},"volume":"Vol.21","number":"No.2","starting_page":"147","ending_page":"156","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1080/15384047.2019.1672455"],"issn":["1555-8576"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113338","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30867708","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=351779","label":"url"}],"paper_title":{"en":"Resveratrol suppresses proliferation and induces apoptosis of uterine sarcoma cells by inhibiting the Wnt signaling pathway.","ja":"Resveratrol suppresses proliferation and induces apoptosis of uterine sarcoma cells by inhibiting the Wnt signaling pathway."},"authors":{"en":[{"name":"Mineda Ayuka"},{"name":"Nishimura Masato"},{"name":"Kagawa Tomohiro"},{"name":"Takiguchi Eri"},{"name":"Kawakita Takako"},{"name":"Abe Akiko"},{"name":"Irahara Minoru"}],"ja":[{"name":"峯田 あゆか"},{"name":"西村 正人"},{"name":"香川 智洋"},{"name":"炬口 恵理"},{"name":"河北 貴子"},{"name":"阿部 彰子"},{"name":"苛原 稔"}]},"description":{"en":"Resveratrol, a natural product and peroxisome proliferator-activated receptor (PPAR) agonist, has been reported to exert anti-cancer effects in several tumor models. A previous study by our group reported that prostaglandin J2, a PPARγ ligand, inhibited cell proliferation in a uterine sarcoma cell line. The aim of the present study was to investigate the role of the Wnt signaling pathway in resveratrol-induced apoptosis and inhibition of cell proliferation in the MES-SA human uterine sarcoma cell line. A WST-1 assay demonstrated that resveratrol inhibited cell proliferation in the MES-SA cell line, and flow cytometry revealed that the number of apoptotic cells increased in a resveratrol dose-dependent manner. The mechanisms underlying these effects of resveratrol were speculated to involve the expression of β-catenin and its target gene, c-myc, which were examined using western blot analysis. The results revealed a dose-dependent downregulation of this β-catenin and c-myc. This effect was blunted by a pharmacological inhibitor of glycogen synthase kinase 3β. Therefore, it is likely that resveratrol inhibited the cell proliferation and increased the number of apoptotic cells, at least partially, via the Wnt signaling pathway. The present results suggest that resveratrol is a potential candidate for the treatment of uterine sarcoma.","ja":"Resveratrol, a natural product and peroxisome proliferator-activated receptor (PPAR) agonist, has been reported to exert anti-cancer effects in several tumor models. A previous study by our group reported that prostaglandin J2, a PPARγ ligand, inhibited cell proliferation in a uterine sarcoma cell line. The aim of the present study was to investigate the role of the Wnt signaling pathway in resveratrol-induced apoptosis and inhibition of cell proliferation in the MES-SA human uterine sarcoma cell line. A WST-1 assay demonstrated that resveratrol inhibited cell proliferation in the MES-SA cell line, and flow cytometry revealed that the number of apoptotic cells increased in a resveratrol dose-dependent manner. The mechanisms underlying these effects of resveratrol were speculated to involve the expression of β-catenin and its target gene, c-myc, which were examined using western blot analysis. The results revealed a dose-dependent downregulation of this β-catenin and c-myc. This effect was blunted by a pharmacological inhibitor of glycogen synthase kinase 3β. Therefore, it is likely that resveratrol inhibited the cell proliferation and increased the number of apoptotic cells, at least partially, via the Wnt signaling pathway. The present results suggest that resveratrol is a potential candidate for the treatment of uterine sarcoma."},"publication_date":"2019-01-28","publication_name":{"en":"Experimental and Therapeutic Medicine","ja":"Experimental and Therapeutic Medicine"},"volume":"Vol.17","number":"No.3","starting_page":"2242","ending_page":"2246","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3892/etm.2019.7209"],"issn":["1792-0981"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112242","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/30282864","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=355354","label":"url"}],"paper_title":{"en":"Can systematic lymphadenectomy be omitted for low-risk endometrial cancer?","ja":"Can systematic lymphadenectomy be omitted for low-risk endometrial cancer?"},"authors":{"en":[{"name":"Yoshida Kanako"},{"name":"Nishimura Masato"},{"name":"Abe Akiko"},{"name":"Katou Takeshi"},{"name":"Furumoto Hiroyuki"},{"name":"Irahara Minoru"}],"ja":[{"name":"吉田 加奈子"},{"name":"西村 正人"},{"name":"阿部 彰子"},{"name":"加藤 剛志"},{"name":"古本 博孝"},{"name":"苛原 稔"}]},"description":{"en":"The objective of this study was to identify pathological indicators that could be used to identify a subgroup of patients with apparent stage I endometrial cancer who do require retroperitoneal lymphadenectomy. 188 T1 endometrial cancer patients underwent primary surgery at Tokushima University Hospital. We retrospectively evaluated their clinical records and histopathological factors. Systematic lymphadenectomy was performed for 149 patients, and 39 patients (grade 1 with < 5 mm of myometrial invasion) were treated without lymphadenectomy. Lymph node metastases were found in 19 (12.8%) of the lymphadenectomy cases. Twenty-four patients with a T1a endometrium-limited lesion did not exhibit lymph node metastasis. Three (3.1%) of the 95 patients with a T1a lesion exhibited lymph node metastasis, and these 3 cases exhibited approximately 50% myometrial invasion. The 39 low-risk patients who did not undergo systematic lymphadenectomy remain alive without recurrence. Systematic lymphadenectomy could be omitted for patients with a grade 1 tumor and minor myometrial invasion of less than 5mm. J. Med. Invest. 65:221-224, August, 2018.","ja":"The objective of this study was to identify pathological indicators that could be used to identify a subgroup of patients with apparent stage I endometrial cancer who do require retroperitoneal lymphadenectomy. 188 T1 endometrial cancer patients underwent primary surgery at Tokushima University Hospital. We retrospectively evaluated their clinical records and histopathological factors. Systematic lymphadenectomy was performed for 149 patients, and 39 patients (grade 1 with < 5 mm of myometrial invasion) were treated without lymphadenectomy. Lymph node metastases were found in 19 (12.8%) of the lymphadenectomy cases. Twenty-four patients with a T1a endometrium-limited lesion did not exhibit lymph node metastasis. Three (3.1%) of the 95 patients with a T1a lesion exhibited lymph node metastasis, and these 3 cases exhibited approximately 50% myometrial invasion. The 39 low-risk patients who did not undergo systematic lymphadenectomy remain alive without recurrence. Systematic lymphadenectomy could be omitted for patients with a grade 1 tumor and minor myometrial invasion of less than 5mm. J. Med. Invest. 65:221-224, August, 2018."},"publication_date":"2018-08","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.65","number":"No.3,4","starting_page":"221","ending_page":"224","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.65.221"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/115584","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29794407","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=340354","label":"url"}],"paper_title":{"en":"A Case of Uterine Tumor Resembling Ovarian Sex-cord Tumor (UTROSCT) Exhibiting Similar Imaging Characteristics to Those of Ovarian Sex-cord Tumor.","ja":"A Case of Uterine Tumor Resembling Ovarian Sex-cord Tumor (UTROSCT) Exhibiting Similar Imaging Characteristics to Those of Ovarian Sex-cord Tumor."},"authors":{"en":[{"name":"Takeuchi Mayumi"},{"name":"Matsuzaki Kenji"},{"name":"Bando Yoshimi"},{"name":"Nishimura Masato"},{"name":"Hayashi Aki"},{"name":"Harada Masafumi"}],"ja":[{"name":"竹内 麻由美"},{"name":"松崎 健司"},{"name":"坂東 良美"},{"name":"西村 正人"},{"name":"林 亜紀"},{"name":"原田 雅史"}]},"publication_date":"2018-05-24","publication_name":{"en":"Magnetic Resonance in Medical Sciences","ja":"Magnetic Resonance in Medical Sciences"},"volume":"Vol.18","number":"No.2","starting_page":"113","ending_page":"114","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2463/mrms.ci.2017-0177"],"issn":["1880-2206"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113734","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85058843418&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=359774","label":"url"}],"paper_title":{"en":"See and treat LEEP biopsy for cervical intraepithelial neoplasia grade 2/3","ja":"See and treat LEEP biopsy for cervical intraepithelial neoplasia grade 2/3"},"authors":{"en":[{"name":"Abe Akiko"},{"name":"Nishimura Masato"},{"name":"Irahara Minoru"}],"ja":[{"name":"阿部 彰子"},{"name":"西村 正人"},{"name":"苛原 稔"}]},"publication_date":"2018-01","publication_name":{"en":"European JOURNAL of Gynaecological Oncology","ja":"European JOURNAL of Gynaecological Oncology"},"volume":"Vol.39","number":"No.6","starting_page":"958","ending_page":"962","languages":["eng"],"referee":true,"identifiers":{"doi":["10.12892/ejgo4391.2018"],"issn":["0392-2936"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112973","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29067110","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339196","label":"url"}],"paper_title":{"en":"Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells.","ja":"Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells."},"authors":{"en":[{"name":"Takiguchi Eri"},{"name":"Nishimura Masato"},{"name":"Mineda Ayuka"},{"name":"Kawakita Takako"},{"name":"Abe Akiko"},{"name":"Irahara Minoru"}],"ja":[{"name":"炬口 恵理"},{"name":"西村 正人"},{"name":"峯田 あゆか"},{"name":"河北 貴子"},{"name":"阿部 彰子"},{"name":"苛原 稔"}]},"description":{"en":"Uterine cervical adenocarcinoma has a poor clinical prognosis when compared with squamous cell carcinoma. Therefore, the development of new treatment strategies for uterine cervical adenocarcinoma is necessary. Src is a proto-oncogene that is important in cancer progression. Dasatinib is a Src inhibitor that has been reported to be effective when used in combination with anticancer drugs. The present study aimed to confirm Src expression in human cervical adenocarcinoma cell lines and to determine the mechanism underlying the inhibitory effect of dasatinib on Src signaling . Western blot analysis was performed to investigate Src expression in cervical adenocarcinoma cell lines (HeLa and TCO-2 cells). The cells were cultured for 48 h with the addition of different concentrations of anticancer drugs (paclitaxel or oxaliplatin). Viable cell count was measured using a colorimetric (WST-1) assay. The concentrations of anticancer agents were fixed according to the results obtained, and the same experiments were performed using the drugs in combination with dasatinib at various concentrations to determine the concentrations that significantly affected the number of viable cells. The presence or absence of apoptosis was investigated using a caspase-3/7 assay. Signal transduction in each cell line was examined using western blotting. Src was activated in the two cell lines, and cell proliferation was significantly suppressed by each anticancer drug in combination with 10 µM dasatinib. Caspase-3/7 activity was also increased and Src signaling was suppressed by each anticancer drug in combination with dasatinib. In conclusion, Src is overexpressed in cervical adenocarcinoma cell lines, and dasatinib inhibits intracellular Src signaling and causes apoptosis. The results of the present study suggest that Src may be targeted in novel therapeutic strategies for cervical adenocarcinoma.","ja":"Uterine cervical adenocarcinoma has a poor clinical prognosis when compared with squamous cell carcinoma. Therefore, the development of new treatment strategies for uterine cervical adenocarcinoma is necessary. Src is a proto-oncogene that is important in cancer progression. Dasatinib is a Src inhibitor that has been reported to be effective when used in combination with anticancer drugs. The present study aimed to confirm Src expression in human cervical adenocarcinoma cell lines and to determine the mechanism underlying the inhibitory effect of dasatinib on Src signaling . Western blot analysis was performed to investigate Src expression in cervical adenocarcinoma cell lines (HeLa and TCO-2 cells). The cells were cultured for 48 h with the addition of different concentrations of anticancer drugs (paclitaxel or oxaliplatin). Viable cell count was measured using a colorimetric (WST-1) assay. The concentrations of anticancer agents were fixed according to the results obtained, and the same experiments were performed using the drugs in combination with dasatinib at various concentrations to determine the concentrations that significantly affected the number of viable cells. The presence or absence of apoptosis was investigated using a caspase-3/7 assay. Signal transduction in each cell line was examined using western blotting. Src was activated in the two cell lines, and cell proliferation was significantly suppressed by each anticancer drug in combination with 10 µM dasatinib. Caspase-3/7 activity was also increased and Src signaling was suppressed by each anticancer drug in combination with dasatinib. In conclusion, Src is overexpressed in cervical adenocarcinoma cell lines, and dasatinib inhibits intracellular Src signaling and causes apoptosis. The results of the present study suggest that Src may be targeted in novel therapeutic strategies for cervical adenocarcinoma."},"publication_date":"2017-08-28","publication_name":{"en":"Experimental and Therapeutic Medicine","ja":"Experimental and Therapeutic Medicine"},"volume":"Vol.14","number":"No.5","starting_page":"4293","ending_page":"4299","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3892/etm.2017.5061"],"issn":["1792-0981"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/116228","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28566585","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-85031280359&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=324801","label":"url"}],"paper_title":{"en":"Ovarian Large Cell Neuroendocrine Carcinoma Associated with Serous Carcinoma: Correlation of Pathology with MR Imaging","ja":"Ovarian Large Cell Neuroendocrine Carcinoma Associated with Serous Carcinoma: Correlation of Pathology with MR Imaging"},"authors":{"en":[{"name":"Takeuchi Mayumi"},{"name":"Matsuzaki Kenji"},{"name":"Tsuneyama Koichi"},{"name":"Nishimura Masato"},{"name":"Takiguchi Eri"},{"name":"Harada Masafumi"}],"ja":[{"name":"竹内 麻由美"},{"name":"松崎 健司"},{"name":"常山 幸一"},{"name":"西村 正人"},{"name":"炬口 恵理"},{"name":"原田 雅史"}]},"publication_date":"2017-05","publication_name":{"en":"Magnetic Resonance in Medical Sciences","ja":"Magnetic Resonance in Medical Sciences"},"volume":"Vol.16","number":"No.4","starting_page":"273","ending_page":"274","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2463/mrms.ci.2016-0150"],"issn":["1880-2206"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/112972","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28587364","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=339206","label":"url"}],"paper_title":{"en":"Cytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma .","ja":"Cytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma ."},"authors":{"en":[{"name":"Kawakita Takako"},{"name":"Nishimura Masato"},{"name":"Takiguchi Eri"},{"name":"Abe Akiko"},{"name":"Irahara Minoru"}],"ja":[{"name":"河北 貴子"},{"name":"西村 正人"},{"name":"炬口 恵理"},{"name":"阿部 彰子"},{"name":"苛原 稔"}]},"description":{"en":"Effective chemotherapeutic strategies for uterine sarcoma are lacking; existing therapies achieve poor response rates. Previous studies have identified the prostaglandin 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) as a potential anticancer treatment; however, its effectiveness in uterine sarcoma has not been examined. Furthermore, the molecular mechanisms underlying the cytotoxic mechanism of 15d-PGJ2 remain unclear. Here, we evaluated the effects of 15d-PGJ2 alone and in combination with the tyrosine kinas inhibitor (TKI) dasatinib in uterine sarcoma cell lines (MES-SA, MES-SA/DX5 and SKN). 15d-PGJ2 inhibited cell growth and increased apoptosis. Western blotting demonstrated that 15d-PGJ2 treatment increased MEK and ERK phosphorylation, and decreased levels of phosphorylated AKT. Dasatinib in combination with 15d-PGJ2 significantly reduced cell proliferation compared with 15d-PGJ2 alone, and repressed both the AKT and MAPK pathways. The cell growth inhibition rate in the PGJ2 was 21.5±12.0, 35.3±5.4 and 28.3±4.2%, respectively (MES-SA, MES-SA/DX5 and SKN cell lines) and the cell growth inhibition rate in the combination therapy was significantly higher compared with 15d-PGJ2 alone (MES-SA; 64.2±0.8, MES-SA/DX5;23.9±8.2 and SKN; 41.4±17.6%). The PGJ2 IC determined by MTT assay was 27.41,10.46 and 17.38 µmol/l, respectively (MES-SA, MES-SA/DX5 and SKN cell lines) and the dasatinib IC was 6.68,17.30 and 6.25 µmol/l, respectively. Our findings demonstrate that 15d-PGJ2 suppresses proliferation by inactivating the AKT pathway in uterine sarcoma. Furthermore, combining 15d-PGJ2 with dasatinib produced a synergistic effect on cancer cell inhibition by repressing 15d-PGJ2-mediated activation of MAPK signaling, and further repressing AKT signaling. These results suggest that 15d-PGJ2 could be used in combination with dasatinib as a potential therapeutic approach for uterine sarcoma.","ja":"Effective chemotherapeutic strategies for uterine sarcoma are lacking; existing therapies achieve poor response rates. Previous studies have identified the prostaglandin 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) as a potential anticancer treatment; however, its effectiveness in uterine sarcoma has not been examined. Furthermore, the molecular mechanisms underlying the cytotoxic mechanism of 15d-PGJ2 remain unclear. Here, we evaluated the effects of 15d-PGJ2 alone and in combination with the tyrosine kinas inhibitor (TKI) dasatinib in uterine sarcoma cell lines (MES-SA, MES-SA/DX5 and SKN). 15d-PGJ2 inhibited cell growth and increased apoptosis. Western blotting demonstrated that 15d-PGJ2 treatment increased MEK and ERK phosphorylation, and decreased levels of phosphorylated AKT. Dasatinib in combination with 15d-PGJ2 significantly reduced cell proliferation compared with 15d-PGJ2 alone, and repressed both the AKT and MAPK pathways. The cell growth inhibition rate in the PGJ2 was 21.5±12.0, 35.3±5.4 and 28.3±4.2%, respectively (MES-SA, MES-SA/DX5 and SKN cell lines) and the cell growth inhibition rate in the combination therapy was significantly higher compared with 15d-PGJ2 alone (MES-SA; 64.2±0.8, MES-SA/DX5;23.9±8.2 and SKN; 41.4±17.6%). The PGJ2 IC determined by MTT assay was 27.41,10.46 and 17.38 µmol/l, respectively (MES-SA, MES-SA/DX5 and SKN cell lines) and the dasatinib IC was 6.68,17.30 and 6.25 µmol/l, respectively. Our findings demonstrate that 15d-PGJ2 suppresses proliferation by inactivating the AKT pathway in uterine sarcoma. Furthermore, combining 15d-PGJ2 with dasatinib produced a synergistic effect on cancer cell inhibition by repressing 15d-PGJ2-mediated activation of MAPK signaling, and further repressing AKT signaling. These results suggest that 15d-PGJ2 could be used in combination with dasatinib as a potential therapeutic approach for uterine sarcoma."},"publication_date":"2017-04-18","publication_name":{"en":"Experimental and Therapeutic Medicine","ja":"Experimental and Therapeutic Medicine"},"volume":"Vol.13","number":"No.6","starting_page":"2939","ending_page":"2945","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3892/etm.2017.4346"],"issn":["1792-0981"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/27052653","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=328251","label":"url"}],"paper_title":{"en":"Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.","ja":"Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma."},"authors":{"en":[{"name":"Matsuo K"},{"name":"Takazawa Y"},{"name":"Ross S. M"},{"name":"Elishaev E"},{"name":"Podzielinski I"},{"name":"Yunokawa M"},{"name":"Sheridan B. T"},{"name":"Bush H. S"},{"name":"Klobocista M. M"},{"name":"Blake A. E"},{"name":"Takano T"},{"name":"Matsuzaki S"},{"name":"Baba T"},{"name":"Satoh S"},{"name":"Shida M"},{"name":"Nishikawa T"},{"name":"Ikeda Y"},{"name":"Adachi S"},{"name":"Yokoyama T"},{"name":"Takekuma M"},{"name":"Fujiwara K"},{"name":"Hazama Y"},{"name":"Kadogami D"},{"name":"Moffitt N. M"},{"name":"Takeuchi S"},{"name":"Nishimura Masato"},{"name":"Iwasaki K"},{"name":"Ushioda N"},{"name":"Johnson S. M"},{"name":"Yoshida M"},{"name":"Hakam A"},{"name":"Li W. S"},{"name":"Richmond M. A"},{"name":"Machida H"},{"name":"Mhawech-Fauceglia P"},{"name":"Ueda Y"},{"name":"Yoshino K"},{"name":"Yamaguchi K"},{"name":"Oishi T"},{"name":"Kajiwara H"},{"name":"Hasegawa K"},{"name":"Yasuda M"},{"name":"Kawana K"},{"name":"Suda K"},{"name":"Miyake M. T"},{"name":"Moriya T"},{"name":"Yuba Y"},{"name":"Morgan T"},{"name":"Fukagawa T"},{"name":"Wakatsuki A"},{"name":"Sugiyama T"},{"name":"Pejovic T"},{"name":"Nagano T"},{"name":"Shimoya K"},{"name":"Andoh M"},{"name":"Shiki Y"},{"name":"Enomoto T"},{"name":"Sasaki T"},{"name":"Fujiwara K"},{"name":"Mikami M"},{"name":"Shimada M"},{"name":"Konishi I"},{"name":"Kimura T"},{"name":"Post D. M"},{"name":"Shahzad M. M"},{"name":"Im D. D"},{"name":"Yoshida H"},{"name":"Omatsu K"},{"name":"Ueland R. F"},{"name":"Kelley L. J"},{"name":"Karabakhtsian G. R"},{"name":"Roman D. L"}],"ja":[{"name":"Matsuo K"},{"name":"Takazawa Y"},{"name":"Ross S. M"},{"name":"Elishaev E"},{"name":"Podzielinski I"},{"name":"Yunokawa M"},{"name":"Sheridan B. T"},{"name":"Bush H. S"},{"name":"Klobocista M. M"},{"name":"Blake A. E"},{"name":"Takano T"},{"name":"Matsuzaki S"},{"name":"Baba T"},{"name":"Satoh S"},{"name":"Shida M"},{"name":"Nishikawa T"},{"name":"Ikeda Y"},{"name":"Adachi S"},{"name":"Yokoyama T"},{"name":"Takekuma M"},{"name":"Fujiwara K"},{"name":"Hazama Y"},{"name":"Kadogami D"},{"name":"Moffitt N. M"},{"name":"Takeuchi S"},{"name":"西村 正人"},{"name":"Iwasaki K"},{"name":"Ushioda N"},{"name":"Johnson S. M"},{"name":"Yoshida M"},{"name":"Hakam A"},{"name":"Li W. S"},{"name":"Richmond M. A"},{"name":"Machida H"},{"name":"Mhawech-Fauceglia P"},{"name":"Ueda Y"},{"name":"Yoshino K"},{"name":"Yamaguchi K"},{"name":"Oishi T"},{"name":"Kajiwara H"},{"name":"Hasegawa K"},{"name":"Yasuda M"},{"name":"Kawana K"},{"name":"Suda K"},{"name":"Miyake M. T"},{"name":"Moriya T"},{"name":"Yuba Y"},{"name":"Morgan T"},{"name":"Fukagawa T"},{"name":"Wakatsuki A"},{"name":"Sugiyama T"},{"name":"Pejovic T"},{"name":"Nagano T"},{"name":"Shimoya K"},{"name":"Andoh M"},{"name":"Shiki Y"},{"name":"Enomoto T"},{"name":"Sasaki T"},{"name":"Fujiwara K"},{"name":"Mikami M"},{"name":"Shimada M"},{"name":"Konishi I"},{"name":"Kimura T"},{"name":"Post D. M"},{"name":"Shahzad M. M"},{"name":"Im D. D"},{"name":"Yoshida H"},{"name":"Omatsu K"},{"name":"Ueland R. F"},{"name":"Kelley L. J"},{"name":"Karabakhtsian G. R"},{"name":"Roman D. L"}]},"description":{"en":"To examine the effect of the histology of carcinoma and sarcoma components on survival outcome of uterine carcinosarcoma. A multicenter retrospective study was conducted to examine uterine carcinosarcoma cases that underwent primary surgical staging. Archived slides were examined and histologic patterns were grouped based on carcinoma (low-grade versus high-grade) and sarcoma (homologous versus heterologous) components, correlating to clinico-pathological demographics and outcomes. Among 1192 cases identified, 906 cases were evaluated for histologic patterns (carcinoma/sarcoma) with high-grade/homologous (40.8%) being the most common type followed by high-grade/heterologous (30.9%), low-grade/homologous (18.0%), and low-grade/heterologous (10.3%). On multivariate analysis, high-grade/heterologous (5-year rate, 34.0%, P = 0.024) and high-grade/homologous (45.8%, P = 0.017) but not low-grade/heterologous (50.6%, P = 0.089) were independently associated with decreased progression-free survival (PFS) compared with low-grade/homologous (60.3%). In addition, older age, residual disease at surgery, large tumor, sarcoma dominance, deep myometrial invasion, lymphovascular space invasion, and advanced-stage disease were independently associated with decreased PFS (all, P < 0.01). Both postoperative chemotherapy (5-year rates, 48.6% versus 39.0%, P < 0.001) and radiotherapy (50.1% versus 44.1%, P = 0.007) were significantly associated with improved PFS in univariate analysis. However, on multivariate analysis, only postoperative chemotherapy remained an independent predictor for improved PFS [hazard ratio (HR) 0.34, 95% confidence interval (CI) 0.27-0.43, P < 0.001]. On univariate analysis, significant treatment benefits for PFS were seen with ifosfamide for low-grade carcinoma (82.0% versus 49.8%, P = 0.001), platinum for high-grade carcinoma (46.9% versus 32.4%, P = 0.034) and homologous sarcoma (53.1% versus 38.2%, P = 0.017), and anthracycline for heterologous sarcoma (66.2% versus 39.3%, P = 0.005). Conversely, platinum, taxane, and anthracycline for low-grade carcinoma, and anthracycline for homologous sarcoma had no effect on PFS compared with non-chemotherapy group (all, P > 0.05). On multivariate analysis, ifosfamide for low-grade/homologous (HR 0.21, 95% CI 0.07-0.63, P = 0.005), platinum for high-grade/homologous (HR 0.36, 95% CI 0.22-0.60, P < 0.001), and anthracycline for high-grade/heterologous (HR 0.30, 95% CI 0.14-0.62, P = 0.001) remained independent predictors for improved PFS. Analyses of 1096 metastatic sites showed that carcinoma components tended to spread lymphatically, while sarcoma components tended to spread loco-regionally (P < 0.001). Characterization of histologic pattern provides valuable information in the management of uterine carcinosarcoma.","ja":"To examine the effect of the histology of carcinoma and sarcoma components on survival outcome of uterine carcinosarcoma. A multicenter retrospective study was conducted to examine uterine carcinosarcoma cases that underwent primary surgical staging. Archived slides were examined and histologic patterns were grouped based on carcinoma (low-grade versus high-grade) and sarcoma (homologous versus heterologous) components, correlating to clinico-pathological demographics and outcomes. Among 1192 cases identified, 906 cases were evaluated for histologic patterns (carcinoma/sarcoma) with high-grade/homologous (40.8%) being the most common type followed by high-grade/heterologous (30.9%), low-grade/homologous (18.0%), and low-grade/heterologous (10.3%). On multivariate analysis, high-grade/heterologous (5-year rate, 34.0%, P = 0.024) and high-grade/homologous (45.8%, P = 0.017) but not low-grade/heterologous (50.6%, P = 0.089) were independently associated with decreased progression-free survival (PFS) compared with low-grade/homologous (60.3%). In addition, older age, residual disease at surgery, large tumor, sarcoma dominance, deep myometrial invasion, lymphovascular space invasion, and advanced-stage disease were independently associated with decreased PFS (all, P < 0.01). Both postoperative chemotherapy (5-year rates, 48.6% versus 39.0%, P < 0.001) and radiotherapy (50.1% versus 44.1%, P = 0.007) were significantly associated with improved PFS in univariate analysis. However, on multivariate analysis, only postoperative chemotherapy remained an independent predictor for improved PFS [hazard ratio (HR) 0.34, 95% confidence interval (CI) 0.27-0.43, P < 0.001]. On univariate analysis, significant treatment benefits for PFS were seen with ifosfamide for low-grade carcinoma (82.0% versus 49.8%, P = 0.001), platinum for high-grade carcinoma (46.9% versus 32.4%, P = 0.034) and homologous sarcoma (53.1% versus 38.2%, P = 0.017), and anthracycline for heterologous sarcoma (66.2% versus 39.3%, P = 0.005). Conversely, platinum, taxane, and anthracycline for low-grade carcinoma, and anthracycline for homologous sarcoma had no effect on PFS compared with non-chemotherapy group (all, P > 0.05). On multivariate analysis, ifosfamide for low-grade/homologous (HR 0.21, 95% CI 0.07-0.63, P = 0.005), platinum for high-grade/homologous (HR 0.36, 95% CI 0.22-0.60, P < 0.001), and anthracycline for high-grade/heterologous (HR 0.30, 95% CI 0.14-0.62, P = 0.001) remained independent predictors for improved PFS. Analyses of 1096 metastatic sites showed that carcinoma components tended to spread lymphatically, while sarcoma components tended to spread loco-regionally (P < 0.001). Characterization of histologic pattern provides valuable information in the management of uterine carcinosarcoma."},"publication_date":"2016-04-06","publication_name":{"en":"Annals of Oncology","ja":"Annals of Oncology"},"volume":"Vol.27","number":"No.7","starting_page":"1257","ending_page":"1266","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1093/annonc/mdw161"],"issn":["1569-8041"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26960725","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=309712","label":"url"}],"paper_title":{"en":"A case of polypoid endometriosis with malignant transformation.","ja":"A case of polypoid endometriosis with malignant transformation."},"authors":{"en":[{"name":"Takeuchi Mayumi"},{"name":"Matsuzaki Kenji"},{"name":"Bando Yoshimi"},{"name":"Nishimura Masato"},{"name":"Yoneda Akiko"},{"name":"Harada Masafumi"}],"ja":[{"name":"竹内 麻由美"},{"name":"松崎 健司"},{"name":"坂東 良美"},{"name":"西村 正人"},{"name":"米田 亜樹子"},{"name":"原田 雅史"}]},"description":{"en":"Polypoid endometriosis is a benign, rare variant of endometriosis which forms multiple polypoid nodules in the female pelvis mimicking malignant tumors; however, it may rarely cause malignant transformation. We report magnetic resonance imaging findings of a case of polypoid endometriosis with malignant transformation. Multiple high-signal intensity polypoid nodules in the cul-de-sac surrounded by low-signal intensity rim-like fibrous adhesion protruding to the posterior wall of the uterine body were demonstrated on T2-weighted images. The polypoid nodules showed weak contrast enhancement compared with that of uterine myometrium on post-contrast T1-weighted images, and slight high signal intensity on diffusion-weighted images with relatively high mean apparent diffusion coefficient. Reported cases of polypoid endometriosis showed intense contrast enhancement similar to that of uterine myometrium, and weak contrast enhancement similar to that of endometrial carcinoma may be suggestive for malignant transformation of polypoid endometriosis.","ja":"Polypoid endometriosis is a benign, rare variant of endometriosis which forms multiple polypoid nodules in the female pelvis mimicking malignant tumors; however, it may rarely cause malignant transformation. We report magnetic resonance imaging findings of a case of polypoid endometriosis with malignant transformation. Multiple high-signal intensity polypoid nodules in the cul-de-sac surrounded by low-signal intensity rim-like fibrous adhesion protruding to the posterior wall of the uterine body were demonstrated on T2-weighted images. The polypoid nodules showed weak contrast enhancement compared with that of uterine myometrium on post-contrast T1-weighted images, and slight high signal intensity on diffusion-weighted images with relatively high mean apparent diffusion coefficient. Reported cases of polypoid endometriosis showed intense contrast enhancement similar to that of uterine myometrium, and weak contrast enhancement similar to that of endometrial carcinoma may be suggestive for malignant transformation of polypoid endometriosis."},"publication_date":"2016-03-10","publication_name":{"en":"Abdominal Radiology","ja":"Abdominal Radiology"},"volume":"Vol.41","number":"No.9","starting_page":"1699","ending_page":"1702","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1007/s00261-016-0696-9"],"issn":["2366-0058"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/111271","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/26399340","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=316936","label":"url"}],"paper_title":{"en":"Clinical Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Invasive Cervical Cancer.","ja":"Clinical Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Invasive Cervical Cancer."},"authors":{"en":[{"name":"Saijo Yasuyo"},{"name":"Furumoto Hiroyuki"},{"name":"Yoshida Kanako"},{"name":"Nishimura Masato"},{"name":"Irahara Minoru"}],"ja":[{"name":"Saijo Yasuyo"},{"name":"Furumoto Hiroyuki"},{"name":"吉田 加奈子"},{"name":"西村 正人"},{"name":"苛原 稔"}]},"description":{"en":"To determine whether vascular endothelial growth factor (VEGF) expression and microvessel density are predictive of prognosis in cases of invasive cervical cancer, correlations among VEGF expression, microvessel density, and clinicopathological parameters were identified. VEGF expression was evaluated in 50 cervical cancer samples by immunohistochemical staining. Microvessel density was assessed by immunostaining for CD31-positive endothelial cells in the most vascularized areas of tumors. VEGF expression and microvessel density were significantly higher in adenocarcinomas than in squamous cell carcinomas. However, in cases of adenocarcinoma, no significant correlations were found among VEGF expression, microvessel density, and clinicopathological parameters. In contrast, for squamous cell carcinomas, microvessel density was significantly higher in cases at an advanced stage and in those with several other poor prognostic factors. The finding that cervical adenocarcinomas exhibited greater VEGF expression and microvessel density than squamous cell carcinomas may explain the poorer prognosis of adenocarcinoma compared with squamous cell carcinoma. Moreover, microvessel density in squamous cell carcinomas was significantly correlated with poor prognostic factors. Therefore, there is possibility that bevacizumab, a humanized monoclonal antibody against VEGF-A, may be useful in the initial treatment targeting angiogenesis for early-stage cervical cancer.","ja":"To determine whether vascular endothelial growth factor (VEGF) expression and microvessel density are predictive of prognosis in cases of invasive cervical cancer, correlations among VEGF expression, microvessel density, and clinicopathological parameters were identified. VEGF expression was evaluated in 50 cervical cancer samples by immunohistochemical staining. Microvessel density was assessed by immunostaining for CD31-positive endothelial cells in the most vascularized areas of tumors. VEGF expression and microvessel density were significantly higher in adenocarcinomas than in squamous cell carcinomas. However, in cases of adenocarcinoma, no significant correlations were found among VEGF expression, microvessel density, and clinicopathological parameters. In contrast, for squamous cell carcinomas, microvessel density was significantly higher in cases at an advanced stage and in those with several other poor prognostic factors. The finding that cervical adenocarcinomas exhibited greater VEGF expression and microvessel density than squamous cell carcinomas may explain the poorer prognosis of adenocarcinoma compared with squamous cell carcinoma. Moreover, microvessel density in squamous cell carcinomas was significantly correlated with poor prognostic factors. Therefore, there is possibility that bevacizumab, a humanized monoclonal antibody against VEGF-A, may be useful in the initial treatment targeting angiogenesis for early-stage cervical cancer."},"publication_date":"2015","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.62","number":"No.3-4","starting_page":"154","ending_page":"160","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.62.154"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"http://ci.nii.ac.jp/naid/10031174208/","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1520009409864859776/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=283788","label":"url"}],"paper_title":{"en":"Effectiveness and tolerability of hysterectomy for the local recurrence of cervical cancer after radiation therapy","ja":"子宮頸癌放射線療法後の局所再発に対する子宮摘出の有用性と安全性について"},"authors":{"en":[{"name":"河見 貴子"},{"name":"Furumoto Hiroyuki"},{"name":"Yoshida Kanako"},{"name":"Katou Takeshi"},{"name":"Nishimura Masato"},{"name":"Irahara Minoru"}],"ja":[{"name":"河見 貴子"},{"name":"古本 博孝"},{"name":"吉田 加奈子"},{"name":"加藤 剛志"},{"name":"西村 正人"},{"name":"苛原 稔"}]},"publication_date":"2013-03-04","publication_name":{"en":"Modern Trends in Obstetrics & Gynecology","ja":"現代産婦人科"},"volume":"Vol.61","number":"No.2","starting_page":"321","ending_page":"324","languages":["jpn"],"referee":true,"identifiers":{"issn":["1882-482X"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"http://ci.nii.ac.jp/naid/40019163514/","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1520009409869175424/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=249044","label":"url"}],"paper_title":{"en":"当院におけるプラチナ耐性再発卵巣癌に対するドキシルの使用経験","ja":"当院におけるプラチナ耐性再発卵巣癌に対するドキシルの使用経験"},"authors":{"en":[{"name":"東元 あゆか"},{"name":"Katou Takeshi"},{"name":"Abe Akiko"},{"name":"海老沢 桂子"},{"name":"Yoshida Kanako"},{"name":"Nishimura Masato"},{"name":"Furumoto Hiroyuki"},{"name":"Irahara Minoru"}],"ja":[{"name":"東元 あゆか"},{"name":"加藤 剛志"},{"name":"阿部 彰子"},{"name":"海老沢 桂子"},{"name":"吉田 加奈子"},{"name":"西村 正人"},{"name":"古本 博孝"},{"name":"苛原 稔"}]},"publication_date":"2011-09-28","publication_name":{"en":"Modern Trends in Obstetrics & Gynecology","ja":"現代産婦人科"},"volume":"Vol.60","number":"No.1","starting_page":"173","ending_page":"177","languages":["jpn"],"referee":true,"identifiers":{"issn":["1882-482X"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/113613","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/21823849","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=355355","label":"url"}],"paper_title":{"en":"The possibility of vertical transmission of human papillomavirus through maternal milk","ja":"The possibility of vertical transmission of human papillomavirus through maternal milk"},"authors":{"en":[{"name":"Yoshida Kanako"},{"name":"Furumoto Hiroyuki"},{"name":"Abe Akiko"},{"name":"Katou Takeshi"},{"name":"Nishimura Masato"},{"name":"Irahara Minoru"}],"ja":[{"name":"吉田 加奈子"},{"name":"古本 博孝"},{"name":"阿部 彰子"},{"name":"加藤 剛志"},{"name":"西村 正人"},{"name":"苛原 稔"}]},"description":{"en":"Human papillomavirus (HPV) DNA has been detected in the oral cavity of infants and breast cancer tissue, suggesting its vertical transmission through maternal milk. We determined whether HPV is detected in maternal milk and is vertically transmitted by breast-feeding. Informed consent was obtained, and maternal milk samples (n=80) were analysed for high-risk HPV DNA. In 43 women, this DNA was measured in the uterine cervix. In women with positive samples, this DNA was measured in the oral cavities of their children. The domain including HPV E6 and E7 was amplified by polymerase chain reaction using consensus primers, and HPV serotype determined by electrophoresis after restriction enzyme digestion. High-risk HPV-16 was detected in two of 80 samples (2.5%), and in these two cases, high-risk HPV was not detected in the uterine cervix or oral cavity of the child. It was concluded that the infection of HPV in maternal milk is rare (2/80); vertical transmission through maternal milk was not detected in this study (0/80). HPV infection through maternal milk may occur, but its likelihood is low.","ja":"Human papillomavirus (HPV) DNA has been detected in the oral cavity of infants and breast cancer tissue, suggesting its vertical transmission through maternal milk. We determined whether HPV is detected in maternal milk and is vertically transmitted by breast-feeding. Informed consent was obtained, and maternal milk samples (n=80) were analysed for high-risk HPV DNA. In 43 women, this DNA was measured in the uterine cervix. In women with positive samples, this DNA was measured in the oral cavities of their children. The domain including HPV E6 and E7 was amplified by polymerase chain reaction using consensus primers, and HPV serotype determined by electrophoresis after restriction enzyme digestion. High-risk HPV-16 was detected in two of 80 samples (2.5%), and in these two cases, high-risk HPV was not detected in the uterine cervix or oral cavity of the child. It was concluded that the infection of HPV in maternal milk is rare (2/80); vertical transmission through maternal milk was not detected in this study (0/80). HPV infection through maternal milk may occur, but its likelihood is low."},"publication_date":"2011-08","publication_name":{"en":"Journal of Obstetrics and Gynaecology","ja":"Journal of Obstetrics and Gynaecology"},"volume":"Vol.31","number":"No.6","starting_page":"503","ending_page":"506","languages":["eng"],"referee":true,"identifiers":{"doi":["10.3109/01443615.2011.570814"],"issn":["1364-6893"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/21795478","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=251356","label":"url"}],"paper_title":{"en":"Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.","ja":"Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer."},"authors":{"en":[{"name":"Hu Wei"},{"name":"Lu Chunhua"},{"name":"Dong Hee Han"},{"name":"Huang Jie"},{"name":"Shen De-yu"},{"name":"Stone L. Rebecca"},{"name":"Nick M. Alpa"},{"name":"Shahzad M. K. Mian"},{"name":"Mora Edna"},{"name":"Jennings B. Nicholas"},{"name":"Lee Joo Sun"},{"name":"Roh Ju-Won"},{"name":"Matsuo Koji"},{"name":"Nishimura Masato"},{"name":"Goodman W. Blake"},{"name":"Jaffe B. Robert"},{"name":"Langley R. Robert"},{"name":"Deavers T. Michael"},{"name":"Lopez-Berestein Gabriel"},{"name":"Coleman L. Robert"},{"name":"Sood K. Anil"}],"ja":[{"name":"Hu Wei"},{"name":"Lu Chunhua"},{"name":"Dong Hee Han"},{"name":"Huang Jie"},{"name":"Shen De-yu"},{"name":"Stone L. Rebecca"},{"name":"Nick M. Alpa"},{"name":"Shahzad M. K. Mian"},{"name":"Mora Edna"},{"name":"Jennings B. Nicholas"},{"name":"Lee Joo Sun"},{"name":"Roh Ju-Won"},{"name":"Matsuo Koji"},{"name":"西村 正人"},{"name":"Goodman W. Blake"},{"name":"Jaffe B. Robert"},{"name":"Langley R. Robert"},{"name":"Deavers T. Michael"},{"name":"Lopez-Berestein Gabriel"},{"name":"Coleman L. Robert"},{"name":"Sood K. Anil"}]},"description":{"en":"Emerging evidence suggests that the Notch/Delta-like ligand 4 (Dll4) pathway may offer important new targets for antiangiogenesis approaches. In this study, we investigated the clinical and biological significance of Dll4 in ovarian cancer. Dll4 was overexpressed in 72% of tumors examined in which it was an independent predictor of poor survival. Patients with tumors responding to anti-VEGF therapy had lower levels of Dll4 than patients with stable or progressive disease. Under hypoxic conditions, VEGF increased Dll4 expression in the tumor vasculature. Immobilized Dll4 also downregulated VEGFR2 expression in endothelial cells directly through methylation of the VEGFR2 promoter. RNAi-mediated silencing of Dll4 in ovarian tumor cells and tumor-associated endothelial cells inhibited cell growth and angiogenesis, accompanied by induction of hypoxia in the tumor microenvironment. Combining Dll4-targeted siRNA with bevacizumab resulted in greater inhibition of tumor growth, compared with control or treatment with bevacizumab alone. Together, our findings establish that Dll4 plays a functionally important role in both the tumor and endothelial compartments of ovarian cancer and that targeting Dll4 in combination with anti-VEGF treatment might improve outcomes of ovarian cancer treatment.","ja":"Emerging evidence suggests that the Notch/Delta-like ligand 4 (Dll4) pathway may offer important new targets for antiangiogenesis approaches. In this study, we investigated the clinical and biological significance of Dll4 in ovarian cancer. Dll4 was overexpressed in 72% of tumors examined in which it was an independent predictor of poor survival. Patients with tumors responding to anti-VEGF therapy had lower levels of Dll4 than patients with stable or progressive disease. Under hypoxic conditions, VEGF increased Dll4 expression in the tumor vasculature. Immobilized Dll4 also downregulated VEGFR2 expression in endothelial cells directly through methylation of the VEGFR2 promoter. RNAi-mediated silencing of Dll4 in ovarian tumor cells and tumor-associated endothelial cells inhibited cell growth and angiogenesis, accompanied by induction of hypoxia in the tumor microenvironment. Combining Dll4-targeted siRNA with bevacizumab resulted in greater inhibition of tumor growth, compared with control or treatment with bevacizumab alone. Together, our findings establish that Dll4 plays a functionally important role in both the tumor and endothelial compartments of ovarian cancer and that targeting Dll4 in combination with anti-VEGF treatment might improve outcomes of ovarian cancer treatment."},"publication_date":"2011-07-27","publication_name":{"en":"Cancer Research","ja":"Cancer Research"},"volume":"Vol.71","number":"No.18","starting_page":"6030","ending_page":"6039","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1158/0008-5472.CAN-10-2719"],"issn":["1538-7445"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/21737505","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=251357","label":"url"}],"paper_title":{"en":"Targeting SRC in mucinous ovarian carcinoma.","ja":"Targeting SRC in mucinous ovarian carcinoma."},"authors":{"en":[{"name":"Matsuo Koji"},{"name":"Nishimura Masato"},{"name":"Bottsford-Miller N. Justin"},{"name":"Huang Jie"},{"name":"Komurov Kakajan"},{"name":"Armaiz-Pena N. Guillermo"},{"name":"Shahzad M. K. Mian"},{"name":"Stone L. Rebecca"},{"name":"Roh Won Ju"},{"name":"Sanguino M. Angela"},{"name":"Lu Chunhua"},{"name":"Im D. Dwight"},{"name":"Rosenshien B. Neil"},{"name":"Sakakibara Atsuko"},{"name":"Nagano Tadayoshi"},{"name":"Yamasaki Masato"},{"name":"Enomoto Takayuki"},{"name":"Kimura Tadashi"},{"name":"Ram T. Prahlad"},{"name":"Schmeler M. Kathleen"},{"name":"Gallick E. Gary"},{"name":"Wong K. Kwong"},{"name":"Frumovitz Michael"},{"name":"Sood K. Anil"}],"ja":[{"name":"Matsuo Koji"},{"name":"西村 正人"},{"name":"Bottsford-Miller N. Justin"},{"name":"Huang Jie"},{"name":"Komurov Kakajan"},{"name":"Armaiz-Pena N. Guillermo"},{"name":"Shahzad M. K. Mian"},{"name":"Stone L. Rebecca"},{"name":"Roh Won Ju"},{"name":"Sanguino M. Angela"},{"name":"Lu Chunhua"},{"name":"Im D. Dwight"},{"name":"Rosenshien B. Neil"},{"name":"Sakakibara Atsuko"},{"name":"Nagano Tadayoshi"},{"name":"Yamasaki Masato"},{"name":"Enomoto Takayuki"},{"name":"Kimura Tadashi"},{"name":"Ram T. Prahlad"},{"name":"Schmeler M. Kathleen"},{"name":"Gallick E. Gary"},{"name":"Wong K. Kwong"},{"name":"Frumovitz Michael"},{"name":"Sood K. Anil"}]},"description":{"en":"Mucinous ovarian carcinomas have a distinct clinical pattern compared with other subtypes of ovarian carcinoma. Here, we evaluated (i) stage-specific clinical significance of mucinous ovarian carcinomas in a large cohort and (ii) the functional role of Src kinase in preclinical models of mucinous ovarian carcinoma. A total of 1,302 ovarian cancer patients including 122 (9.4%) cases of mucinous carcinoma were evaluated for survival analyses. Biological effects of Src kinase inhibition were tested using dasatinib-based therapy in a novel orthotopic mucinous ovarian cancer model (RMUG-S-ip2). Patients with advanced-stage mucinous ovarian cancer had significantly worse survival than those with serous histology: median overall survival, 1.67 versus 3.41 years, P = 0.002; median survival time after recurrence of 0.53 versus 1.66 years, P < 0.0001. Among multiple ovarian cancer cell lines, RMUG-S-ip2 mucinous ovarian cancer cells showed the highest Src kinase activity. Moreover, oxaliplatin treatment induced phosphorylation of Src kinase. This induced activity by oxaliplatin therapy was inhibited by concurrent administration of dasatinib. Targeting Src with dasatinib in vivo showed significant antitumor effects in the RMUG-S-ip2 model but not in the serous ovarian carcinoma (SKOV3-TR) model. Combination therapy of oxaliplatin with dasatinib further showed significant effects on reducing cell viability, increasing apoptosis, and in vivo antitumor effects in the RMUG-S-ip2 model. Our results suggest that poor survival of women with mucinous ovarian carcinoma is associated with resistance to cytotoxic therapy. Targeting Src kinase with a combination of dasatinib and oxaliplatin may be an attractive approach for this disease.","ja":"Mucinous ovarian carcinomas have a distinct clinical pattern compared with other subtypes of ovarian carcinoma. Here, we evaluated (i) stage-specific clinical significance of mucinous ovarian carcinomas in a large cohort and (ii) the functional role of Src kinase in preclinical models of mucinous ovarian carcinoma. A total of 1,302 ovarian cancer patients including 122 (9.4%) cases of mucinous carcinoma were evaluated for survival analyses. Biological effects of Src kinase inhibition were tested using dasatinib-based therapy in a novel orthotopic mucinous ovarian cancer model (RMUG-S-ip2). Patients with advanced-stage mucinous ovarian cancer had significantly worse survival than those with serous histology: median overall survival, 1.67 versus 3.41 years, P = 0.002; median survival time after recurrence of 0.53 versus 1.66 years, P < 0.0001. Among multiple ovarian cancer cell lines, RMUG-S-ip2 mucinous ovarian cancer cells showed the highest Src kinase activity. Moreover, oxaliplatin treatment induced phosphorylation of Src kinase. This induced activity by oxaliplatin therapy was inhibited by concurrent administration of dasatinib. Targeting Src with dasatinib in vivo showed significant antitumor effects in the RMUG-S-ip2 model but not in the serous ovarian carcinoma (SKOV3-TR) model. Combination therapy of oxaliplatin with dasatinib further showed significant effects on reducing cell viability, increasing apoptosis, and in vivo antitumor effects in the RMUG-S-ip2 model. Our results suggest that poor survival of women with mucinous ovarian carcinoma is associated with resistance to cytotoxic therapy. Targeting Src kinase with a combination of dasatinib and oxaliplatin may be an attractive approach for this disease."},"publication_date":"2011-07-07","publication_name":{"en":"Clinical Cancer Research","ja":"Clinical Cancer Research"},"volume":"Vol.17","number":"No.16","starting_page":"5367","ending_page":"5378","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1158/1078-0432.CCR-10-3176"],"issn":["1078-0432"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/21358280","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=251359","label":"url"}],"paper_title":{"en":"Chitosan hydrogel for localized gene silencing.","ja":"Chitosan hydrogel for localized gene silencing."},"authors":{"en":[{"name":"Han Dong Hee"},{"name":"Mora M. Edna"},{"name":"Roh Won Ju"},{"name":"Nishimura Masato"},{"name":"Lee Joo Sun"},{"name":"Stone L. Rebecca"},{"name":"Bar-Eli Menashe"},{"name":"Lopez-Berestein Gabriel"},{"name":"Sood K. Anil"}],"ja":[{"name":"Han Dong Hee"},{"name":"Mora M. Edna"},{"name":"Roh Won Ju"},{"name":"西村 正人"},{"name":"Lee Joo Sun"},{"name":"Stone L. Rebecca"},{"name":"Bar-Eli Menashe"},{"name":"Lopez-Berestein Gabriel"},{"name":"Sood K. Anil"}]},"description":{"en":"To achieve effective delivery of siRNA into target cells in vivo, we have developed a novel approach of siRNA delivery by using local drug delivery systems. The chitosan hydrogel (CH-HG) displayed a liquid-solid phase transition in a temperature-dependent manner and formed an endothermic hydrogel in tumor tissue after intra-tumoral injection. Additionally, we tested the extent of in vivo delivery following a single intra-tumoral injection of Alexa555 siRNA/CH-HG into A375SM-bearing mice. The Alexa555 siRNA demonstrated higher localization into tumor cells compared to control. The Alexa555 siRNA delivery extends to tumor cells outside of CH-HG and some tumor cells also infiltrated into CH-HG. For therapeutic proof-of-concept studies, CH-HG including TG2-targeted siRNA significantly inhibited tumor growth in melanoma (A375SM) and breast (MDA-MB231) tumor models compared to control (A375SM: 72% reduction and MDA-MB231: 92% reduction, p < 0.001). we prepared a CH-HG system loaded with siRNA to enhance localized therapeutic efficacy without risk for systemic side effects. Delivery of siRNA into CH-HG was confirmed by fluorescence microscopy. Antitumor efficacy was examined in mouse models of melanoma (A375SM) and breast (MDA-MD231) cancer. This study developed a novel local delivery method for siRNA therapy using the CH-HG system. This approach could have broad applications for multiple localized diseases.","ja":"To achieve effective delivery of siRNA into target cells in vivo, we have developed a novel approach of siRNA delivery by using local drug delivery systems. The chitosan hydrogel (CH-HG) displayed a liquid-solid phase transition in a temperature-dependent manner and formed an endothermic hydrogel in tumor tissue after intra-tumoral injection. Additionally, we tested the extent of in vivo delivery following a single intra-tumoral injection of Alexa555 siRNA/CH-HG into A375SM-bearing mice. The Alexa555 siRNA demonstrated higher localization into tumor cells compared to control. The Alexa555 siRNA delivery extends to tumor cells outside of CH-HG and some tumor cells also infiltrated into CH-HG. For therapeutic proof-of-concept studies, CH-HG including TG2-targeted siRNA significantly inhibited tumor growth in melanoma (A375SM) and breast (MDA-MB231) tumor models compared to control (A375SM: 72% reduction and MDA-MB231: 92% reduction, p < 0.001). we prepared a CH-HG system loaded with siRNA to enhance localized therapeutic efficacy without risk for systemic side effects. Delivery of siRNA into CH-HG was confirmed by fluorescence microscopy. Antitumor efficacy was examined in mouse models of melanoma (A375SM) and breast (MDA-MD231) cancer. This study developed a novel local delivery method for siRNA therapy using the CH-HG system. This approach could have broad applications for multiple localized diseases."},"publication_date":"2011-05-01","publication_name":{"en":"Cancer Biology & Therapy","ja":"Cancer Biology & Therapy"},"volume":"Vol.11","number":"No.9","starting_page":"839","ending_page":"845","languages":["eng"],"referee":true,"identifiers":{"doi":["10.4161/cbt.11.9.15185"],"issn":["1555-8576"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/21472135","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=251358","label":"url"}],"paper_title":{"en":"Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.","ja":"Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles."},"authors":{"en":[{"name":"Shahzad M. K. Mian"},{"name":"Mangala S. Lingegowda"},{"name":"Han Dong Hee"},{"name":"Lu Chunhua"},{"name":"Bottsford-Miller Justin"},{"name":"Nishimura Masato"},{"name":"Mora M. Edna"},{"name":"Lee Jeong-Won"},{"name":"Stone L. Rebecca"},{"name":"Pecot V. Chad"},{"name":"Thanapprapasr Duangmani"},{"name":"Roh Ju-Won"},{"name":"Gaur Puja"},{"name":"Nair P. Maya"},{"name":"Park Yun-Yong"},{"name":"Sabnis Nirupama"},{"name":"Deavers T. Michael"},{"name":"Lee Ju-Seog"},{"name":"Ellis M. Lee"},{"name":"Lopez-Berestein Gabriel"},{"name":"McConathy J. Walter"},{"name":"Prokai Laszlo"},{"name":"Lacko G. Andras"},{"name":"Sood K. Anil"}],"ja":[{"name":"Shahzad M. K. Mian"},{"name":"Mangala S. Lingegowda"},{"name":"Han Dong Hee"},{"name":"Lu Chunhua"},{"name":"Bottsford-Miller Justin"},{"name":"西村 正人"},{"name":"Mora M. Edna"},{"name":"Lee Jeong-Won"},{"name":"Stone L. Rebecca"},{"name":"Pecot V. Chad"},{"name":"Thanapprapasr Duangmani"},{"name":"Roh Ju-Won"},{"name":"Gaur Puja"},{"name":"Nair P. Maya"},{"name":"Park Yun-Yong"},{"name":"Sabnis Nirupama"},{"name":"Deavers T. Michael"},{"name":"Lee Ju-Seog"},{"name":"Ellis M. Lee"},{"name":"Lopez-Berestein Gabriel"},{"name":"McConathy J. Walter"},{"name":"Prokai Laszlo"},{"name":"Lacko G. Andras"},{"name":"Sood K. Anil"}]},"description":{"en":"RNA interference holds tremendous potential as a therapeutic approach, especially in the treatment of malignant tumors. However, efficient and biocompatible delivery methods are needed for systemic delivery of small interfering RNA (siRNA). To maintain a high level of growth, tumor cells scavenge high-density lipoprotein (HDL) particles by overexpressing its receptor: scavenger receptor type B1 (SR-B1). In this study, we exploited this cellular characteristic to achieve efficient siRNA delivery and established a novel formulation of siRNA by incorporating it into reconstituted HDL (rHDL) nanoparticles. Here, we demonstrate that rHDL nanoparticles facilitate highly efficient systemic delivery of siRNA in vivo, mediated by the SR-B1. Moreover, in therapeutic proof-of-concept studies, these nanoparticles were effective in silencing the expression of two proteins that are key to cancer growth and metastasis (signal transducer and activator of transcription 3 and focal adhesion kinase) in orthotopic mouse models of ovarian and colorectal cancer. These data indicate that an rHDL nanoparticle is a novel and highly efficient siRNA carrier, and therefore, this novel technology could serve as the foundation for new cancer therapeutic approaches.","ja":"RNA interference holds tremendous potential as a therapeutic approach, especially in the treatment of malignant tumors. However, efficient and biocompatible delivery methods are needed for systemic delivery of small interfering RNA (siRNA). To maintain a high level of growth, tumor cells scavenge high-density lipoprotein (HDL) particles by overexpressing its receptor: scavenger receptor type B1 (SR-B1). In this study, we exploited this cellular characteristic to achieve efficient siRNA delivery and established a novel formulation of siRNA by incorporating it into reconstituted HDL (rHDL) nanoparticles. Here, we demonstrate that rHDL nanoparticles facilitate highly efficient systemic delivery of siRNA in vivo, mediated by the SR-B1. Moreover, in therapeutic proof-of-concept studies, these nanoparticles were effective in silencing the expression of two proteins that are key to cancer growth and metastasis (signal transducer and activator of transcription 3 and focal adhesion kinase) in orthotopic mouse models of ovarian and colorectal cancer. These data indicate that an rHDL nanoparticle is a novel and highly efficient siRNA carrier, and therefore, this novel technology could serve as the foundation for new cancer therapeutic approaches."},"publication_date":"2011-04","publication_name":{"en":"Neoplasia","ja":"Neoplasia"},"volume":"Vol.13","number":"No.4","starting_page":"309","ending_page":"319","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1593/neo.101372"],"issn":["1476-5586"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/21300758","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=251360","label":"url"}],"paper_title":{"en":"Functional roles of Src and Fgr in ovarian carcinoma.","ja":"Functional roles of Src and Fgr in ovarian carcinoma."},"authors":{"en":[{"name":"Kim Hye-Sun"},{"name":"Han Dong Hee"},{"name":"Armaiz-Pena N. Guillermo"},{"name":"Stone L. Rebecca"},{"name":"Nam Ji Eun"},{"name":"Lee Jeong-Won"},{"name":"Shahzad M. K. Mian"},{"name":"Nick M. Alpa"},{"name":"Lee Joo Sun"},{"name":"Roh Ju-Won"},{"name":"Nishimura Masato"},{"name":"Mangala S. Lingegowda"},{"name":"Bottsford-Miller Justin"},{"name":"Gallick E. Gary"},{"name":"Lopez-Berestein Gabriel"},{"name":"Sood K. Anil"}],"ja":[{"name":"Kim Hye-Sun"},{"name":"Han Dong Hee"},{"name":"Armaiz-Pena N. Guillermo"},{"name":"Stone L. Rebecca"},{"name":"Nam Ji Eun"},{"name":"Lee Jeong-Won"},{"name":"Shahzad M. K. Mian"},{"name":"Nick M. Alpa"},{"name":"Lee Joo Sun"},{"name":"Roh Ju-Won"},{"name":"西村 正人"},{"name":"Mangala S. Lingegowda"},{"name":"Bottsford-Miller Justin"},{"name":"Gallick E. Gary"},{"name":"Lopez-Berestein Gabriel"},{"name":"Sood K. Anil"}]},"description":{"en":"Src is an attractive target because it is overexpressed in a number of malignancies, including ovarian cancer. However, the effect of Src silencing on other Src family kinases (SFKs) is not known. We hypothesized that other SFK members could compensate for the lack of Src activity. Cell viability after either Src or Fgr silencing was examined in ovarian cancer cell lines by MTT assay. Expression of SFKs after Src silencing in ovarian cancer cells was examined by real-time reverse transcriptase (RT)-PCR. Therapeutic effect of in vivo Src and/or Fgr silencing was examined using siRNA incorporated into chitosan nanoparticles (siRNA/CH-NP). Microvessel density, cell proliferation, and apoptosis markers were determined by immunohistochemical staining in ovarian tumor tissues. Src silencing enhanced cytotoxicity of docetaxel in both SKOV3ip1 and HeyA8 cells. In addition, Src silencing using siRNA/CH-NP in combination with docetaxel resulted in significant inhibition of tumor growth compared with control siRNA/CH-NP (81.8% reduction in SKOV3ip1, P = 0.017; 84.3% reduction in HeyA8, P < 0.005). These effects were mediated by decreased tumor cell proliferation and angiogenesis, and increased tumor cell apoptosis. Next, we assessed the effects of Src silencing on other SFK members in ovarian cancer cell lines. Src silencing resulted in significantly increased Fgr levels. Dual Src and Fgr silencing in vitro resulted in increased apoptosis that was mediated by increased caspase and AKT activity. In addition, dual silencing of Src and Fgr in vivo using siRNA/CH-NP resulted in the greatest reduction in tumor growth compared with silencing of either Src or Fgr alone in the HeyA8 model (68.8%, P < 0.05). This study demonstrates that, in addition to Src, Fgr plays a biologically significant role in ovarian cancer growth and might represent an important target.","ja":"Src is an attractive target because it is overexpressed in a number of malignancies, including ovarian cancer. However, the effect of Src silencing on other Src family kinases (SFKs) is not known. We hypothesized that other SFK members could compensate for the lack of Src activity. Cell viability after either Src or Fgr silencing was examined in ovarian cancer cell lines by MTT assay. Expression of SFKs after Src silencing in ovarian cancer cells was examined by real-time reverse transcriptase (RT)-PCR. Therapeutic effect of in vivo Src and/or Fgr silencing was examined using siRNA incorporated into chitosan nanoparticles (siRNA/CH-NP). Microvessel density, cell proliferation, and apoptosis markers were determined by immunohistochemical staining in ovarian tumor tissues. Src silencing enhanced cytotoxicity of docetaxel in both SKOV3ip1 and HeyA8 cells. In addition, Src silencing using siRNA/CH-NP in combination with docetaxel resulted in significant inhibition of tumor growth compared with control siRNA/CH-NP (81.8% reduction in SKOV3ip1, P = 0.017; 84.3% reduction in HeyA8, P < 0.005). These effects were mediated by decreased tumor cell proliferation and angiogenesis, and increased tumor cell apoptosis. Next, we assessed the effects of Src silencing on other SFK members in ovarian cancer cell lines. Src silencing resulted in significantly increased Fgr levels. Dual Src and Fgr silencing in vitro resulted in increased apoptosis that was mediated by increased caspase and AKT activity. In addition, dual silencing of Src and Fgr in vivo using siRNA/CH-NP resulted in the greatest reduction in tumor growth compared with silencing of either Src or Fgr alone in the HeyA8 model (68.8%, P < 0.05). This study demonstrates that, in addition to Src, Fgr plays a biologically significant role in ovarian cancer growth and might represent an important target."},"publication_date":"2011-02-07","publication_name":{"en":"Clinical Cancer Research","ja":"Clinical Cancer Research"},"volume":"Vol.17","number":"No.7","starting_page":"1713","ending_page":"1721","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1158/1078-0432.CCR-10-2081"],"issn":["1078-0432"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/20826776","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=238143","label":"url"}],"paper_title":{"en":"Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.","ja":"Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis."},"authors":{"en":[{"name":"Shahzad MM"},{"name":"Arevalo JM"},{"name":"Armaiz-Pena GN"},{"name":"Lu C"},{"name":"Stone RL"},{"name":"Moreno-Smith M"},{"name":"Nishimura Masato"},{"name":"Lee JW"},{"name":"Jennings NB"},{"name":"Bottsford-Miller J"},{"name":"Vivas-Mejia P"},{"name":"Lutgendorf SK"},{"name":"Lopez-Berestein G"},{"name":"Bar-Eli M"},{"name":"Cole SW"},{"name":"Sood AK"}],"ja":[{"name":"Shahzad MM"},{"name":"Arevalo JM"},{"name":"Armaiz-Pena GN"},{"name":"Lu C"},{"name":"Stone RL"},{"name":"Moreno-Smith M"},{"name":"西村 正人"},{"name":"Lee JW"},{"name":"Jennings NB"},{"name":"Bottsford-Miller J"},{"name":"Vivas-Mejia P"},{"name":"Lutgendorf SK"},{"name":"Lopez-Berestein G"},{"name":"Bar-Eli M"},{"name":"Cole SW"},{"name":"Sood AK"}]},"description":{"en":"A growing number of studies indicate that chronic stress can accelerate tumor growth due to sustained sympathetic nervous system activation. Our recent findings suggest that chronic stress is associated with increased IL8 levels. Here, we examined the molecular and biological significance of IL8 in stress-induced tumor growth. Norepinephrine (NE) treatment of ovarian cancer cells resulted in a 250-300% increase in IL8 protein and 240-320% increase in its mRNA levels. Epinephrine treatment resulted in similar increases. Moreover, NE treatment resulted in a 3.5-4-fold increase in IL8 promoter activity. These effects were blocked by propranolol. Promoter deletion analyses suggested that AP1 transcription factors might mediate catecholamine-stimulated up-regulation of IL8. siRNA inhibition studies identified FosB as the pivotal component responsible for IL8 regulation by NE. In vivo chronic stress resulted in increased tumor growth (by 221 and 235%; p < 0.01) in orthotopic xenograft models involving SKOV3ip1 and HeyA8 ovarian carcinoma cells. This enhanced tumor growth was completely blocked by IL8 or FosB gene silencing using 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine nanoliposomes. IL8 and FosB silencing reduced microvessel density (based on CD31 staining) by 2.5- and 3.5-fold, respectively (p < 0.001). Our findings indicate that neurobehavioral stress leads to FosB-driven increases in IL8, which is associated with increased tumor growth and metastases. These findings may have implications for ovarian cancer management.","ja":"A growing number of studies indicate that chronic stress can accelerate tumor growth due to sustained sympathetic nervous system activation. Our recent findings suggest that chronic stress is associated with increased IL8 levels. Here, we examined the molecular and biological significance of IL8 in stress-induced tumor growth. Norepinephrine (NE) treatment of ovarian cancer cells resulted in a 250-300% increase in IL8 protein and 240-320% increase in its mRNA levels. Epinephrine treatment resulted in similar increases. Moreover, NE treatment resulted in a 3.5-4-fold increase in IL8 promoter activity. These effects were blocked by propranolol. Promoter deletion analyses suggested that AP1 transcription factors might mediate catecholamine-stimulated up-regulation of IL8. siRNA inhibition studies identified FosB as the pivotal component responsible for IL8 regulation by NE. In vivo chronic stress resulted in increased tumor growth (by 221 and 235%; p < 0.01) in orthotopic xenograft models involving SKOV3ip1 and HeyA8 ovarian carcinoma cells. This enhanced tumor growth was completely blocked by IL8 or FosB gene silencing using 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine nanoliposomes. IL8 and FosB silencing reduced microvessel density (based on CD31 staining) by 2.5- and 3.5-fold, respectively (p < 0.001). Our findings indicate that neurobehavioral stress leads to FosB-driven increases in IL8, which is associated with increased tumor growth and metastases. These findings may have implications for ovarian cancer management."},"publication_date":"2010-09-08","publication_name":{"en":"The Journal of Biological Chemistry","ja":"The Journal of Biological Chemistry"},"volume":"Vol.285","number":"No.46","starting_page":"35462","ending_page":"35470","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1074/jbc.M110.109579"],"issn":["1083-351X"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/20682653","label":"url"},{"@id":"https://www.scopus.com/record/display.url?eid=2-s2.0-77955484001&origin=inward","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=238150","label":"url"}],"paper_title":{"en":"Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.","ja":"Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma."},"authors":{"en":[{"name":"Spannuth WA"},{"name":"Mangala LS"},{"name":"Stone RL"},{"name":"Carroll AR"},{"name":"Nishimura Masato"},{"name":"Shahzad MM"},{"name":"Lee SJ"},{"name":"Moreno-Smith M"},{"name":"Nick AM"},{"name":"Liu R"},{"name":"Jennings NB"},{"name":"Lin YG"},{"name":"Merritt WM"},{"name":"Coleman RL"},{"name":"Vivas-Mejia PE"},{"name":"Zhou Y"},{"name":"Krasnoperov V"},{"name":"Lopez-Berestein G"},{"name":"Gill PS"},{"name":"Sood AK"}],"ja":[{"name":"Spannuth WA"},{"name":"Mangala LS"},{"name":"Stone RL"},{"name":"Carroll AR"},{"name":"西村 正人"},{"name":"Shahzad MM"},{"name":"Lee SJ"},{"name":"Moreno-Smith M"},{"name":"Nick AM"},{"name":"Liu R"},{"name":"Jennings NB"},{"name":"Lin YG"},{"name":"Merritt WM"},{"name":"Coleman RL"},{"name":"Vivas-Mejia PE"},{"name":"Zhou Y"},{"name":"Krasnoperov V"},{"name":"Lopez-Berestein G"},{"name":"Gill PS"},{"name":"Sood AK"}]},"description":{"en":"EphB4 is a transmembrane receptor tyrosine kinase that plays an important role in neural plasticity and angiogenesis. EphB4 is overexpressed in ovarian cancer and is predictive of poor clinical outcome. However, the biological significance of EphB4 in ovarian cancer is not known and is the focus of the current study. Here, we examined the biological effects of two different methods of EphB4 targeting (a novel monoclonal antibody, EphB4-131 or siRNA) using several ovarian cancer models. EphB4 gene silencing significantly increased tumor cell apoptosis and decreased migration (P < 0.001) and invasion (P < 0.001). Compared with controls, EphB4 siRNA-1,2-dioleoyl-sn-glycero-3-phosphatidylcholine alone significantly reduced tumor growth in the A2780-cp20 (48%, P < 0.05) and IGROV-af1 (61%, P < 0.05) models. Combination therapy with EphB4 siRNA-1,2-dioleoyl-sn-glycero-3-phosphatidylcholine and docetaxel resulted in the greatest reduction in tumor weight in both A2780-cp20 and IGROV-af1 models (89-95% reduction versus controls; P < 0.05 for both groups). The EphB4-131 antibody, which reduced EphB4 protein levels, decreased tumor growth by 80% to 83% (P < 0.01 for both models) in A2780-cp20 and IGROV-af1 models. The combination of EphB4-131 and docetaxel resulted in the greatest tumor reduction in both A2780-cp20 and IGROV-af1 models (94-98% reduction versus controls; P < 0.05 for both groups). Compared with controls, EphB4 targeting resulted in reduced tumor angiogenesis (P < 0.001), proliferation (P < 0.001), and increased tumor cell apoptosis (P < 0.001), which likely occur through modulation of phosphoinositide 3-kinase signaling. Collectively, these data identify EphB4 as a valuable therapeutic target in ovarian cancer and offer two new strategies for further development.","ja":"EphB4 is a transmembrane receptor tyrosine kinase that plays an important role in neural plasticity and angiogenesis. EphB4 is overexpressed in ovarian cancer and is predictive of poor clinical outcome. However, the biological significance of EphB4 in ovarian cancer is not known and is the focus of the current study. Here, we examined the biological effects of two different methods of EphB4 targeting (a novel monoclonal antibody, EphB4-131 or siRNA) using several ovarian cancer models. EphB4 gene silencing significantly increased tumor cell apoptosis and decreased migration (P < 0.001) and invasion (P < 0.001). Compared with controls, EphB4 siRNA-1,2-dioleoyl-sn-glycero-3-phosphatidylcholine alone significantly reduced tumor growth in the A2780-cp20 (48%, P < 0.05) and IGROV-af1 (61%, P < 0.05) models. Combination therapy with EphB4 siRNA-1,2-dioleoyl-sn-glycero-3-phosphatidylcholine and docetaxel resulted in the greatest reduction in tumor weight in both A2780-cp20 and IGROV-af1 models (89-95% reduction versus controls; P < 0.05 for both groups). The EphB4-131 antibody, which reduced EphB4 protein levels, decreased tumor growth by 80% to 83% (P < 0.01 for both models) in A2780-cp20 and IGROV-af1 models. The combination of EphB4-131 and docetaxel resulted in the greatest tumor reduction in both A2780-cp20 and IGROV-af1 models (94-98% reduction versus controls; P < 0.05 for both groups). Compared with controls, EphB4 targeting resulted in reduced tumor angiogenesis (P < 0.001), proliferation (P < 0.001), and increased tumor cell apoptosis (P < 0.001), which likely occur through modulation of phosphoinositide 3-kinase signaling. Collectively, these data identify EphB4 as a valuable therapeutic target in ovarian cancer and offer two new strategies for further development."},"publication_date":"2010-08-03","publication_name":{"en":"Molecular Cancer Therapeutics","ja":"Molecular Cancer Therapeutics"},"volume":"Vol.9","number":"No.8","starting_page":"2377","ending_page":"2388","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1158/1535-7163.MCT-10-0200"],"issn":["1538-8514"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://repo.lib.tokushima-u.ac.jp/ja/67872","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/20299756","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=209103","label":"url"}],"paper_title":{"en":"A huge ovarian smooth muscle tumor: a case report.","ja":"A huge ovarian smooth muscle tumor: a case report."},"authors":{"en":[{"name":"Murakami Masahiro"},{"name":"Uehara Hisanori"},{"name":"Nishimura Masato"},{"name":"Iwasa Takeshi"},{"name":"Ikawa Hiroshi"}],"ja":[{"name":"Murakami Masahiro"},{"name":"Uehara Hisanori"},{"name":"西村 正人"},{"name":"岩佐 武"},{"name":"Ikawa Hiroshi"}]},"description":{"en":"Ovarian smooth muscle tumors are a very rare type of ovarian tumor. In this paper, we report the case of a 62-year-old woman who had a huge smooth muscle tumor of the right ovary. The values of all the serum tumor markers were within normal limit. The tumor measured 25 cm in diameter and weighed 6,200 g. Histological examination revealed that coagulative cellular atypia was moderate to severe, necrosis was not present and mitotic index was low. According to the criteria for the evaluation of the uterine smooth muscle tumors, this huge tumor was diagnosed as atypical leiomyoma. However, we finally made a diagnosis of this tumor as a smooth muscle tumor of uncertain malignant potential (STUMP) because of its huge size. Further information is required regarding the characteristics of ovarian smooth muscle tumor and the propriety to introduce uterine tumor histological criteria to ovarian tumors.","ja":"Ovarian smooth muscle tumors are a very rare type of ovarian tumor. In this paper, we report the case of a 62-year-old woman who had a huge smooth muscle tumor of the right ovary. The values of all the serum tumor markers were within normal limit. The tumor measured 25 cm in diameter and weighed 6,200 g. Histological examination revealed that coagulative cellular atypia was moderate to severe, necrosis was not present and mitotic index was low. According to the criteria for the evaluation of the uterine smooth muscle tumors, this huge tumor was diagnosed as atypical leiomyoma. However, we finally made a diagnosis of this tumor as a smooth muscle tumor of uncertain malignant potential (STUMP) because of its huge size. Further information is required regarding the characteristics of ovarian smooth muscle tumor and the propriety to introduce uterine tumor histological criteria to ovarian tumors."},"publication_date":"2010","publication_name":{"en":"The Journal of Medical Investigation : JMI","ja":"The Journal of Medical Investigation : JMI"},"volume":"Vol.57","number":"No.1-2","starting_page":"158","ending_page":"162","languages":["eng"],"referee":true,"identifiers":{"doi":["10.2152/jmi.57.158"],"issn":["1349-6867"]},"published_paper_type":"scientific_journal"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"http://id.ndl.go.jp/bib/031887458","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1520290885604307712/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=390231","label":"url"}],"paper_title":{"en":"術前に卵巣原発胚細胞性腫瘍を疑ったが, 傍卵巣の平滑筋肉腫であった一例","ja":"術前に卵巣原発胚細胞性腫瘍を疑ったが, 傍卵巣の平滑筋肉腫であった一例"},"authors":{"en":[{"name":"篠原 文香"},{"name":"Mineda Ayuka"},{"name":"乾 宏彰"},{"name":"Kagawa Tomohiro"},{"name":"阿部 彰子"},{"name":"西條 康代"},{"name":"Nishimura Masato"},{"name":"Irahara Minoru"},{"name":"Iwasa Takeshi"}],"ja":[{"name":"篠原 文香"},{"name":"峯田 あゆか"},{"name":"乾 宏彰"},{"name":"香川 智洋"},{"name":"阿部 彰子"},{"name":"西條 康代"},{"name":"西村 正人"},{"name":"苛原 稔"},{"name":"岩佐 武"}]},"publication_date":"2021-12-10","publication_name":{"en":"Modern Trends in Obstetrics & Gynecology","ja":"現代産婦人科"},"volume":"Vol.70","number":"No.1","starting_page":"227","ending_page":"231","languages":["jpn"],"identifiers":{"issn":["1882-482X"]},"published_paper_type":"research_institution"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"http://id.ndl.go.jp/bib/031887209","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1520853835559930496/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=390228","label":"url"}],"paper_title":{"en":"子宮内膜癌・子宮内膜異型増殖症に対する妊孕性温存治療の治療効果と妊娠成績,周産期予後","ja":"子宮内膜癌・子宮内膜異型増殖症に対する妊孕性温存治療の治療効果と妊娠成績,周産期予後"},"authors":{"en":[{"name":"田村 公"},{"name":"Yamamoto Yuri"},{"name":"Minato Saki"},{"name":"柳原 里江"},{"name":"Kamada Shuhei"},{"name":"谷口 友香"},{"name":"阿部 彰子"},{"name":"Nishimura Masato"},{"name":"Irahara Minoru"},{"name":"Iwasa Takeshi"}],"ja":[{"name":"田村 公"},{"name":"山本 由理"},{"name":"湊 沙希"},{"name":"柳原 里江"},{"name":"鎌田 周平"},{"name":"谷口 友香"},{"name":"阿部 彰子"},{"name":"西村 正人"},{"name":"苛原 稔"},{"name":"岩佐 武"}]},"publication_date":"2021-12-10","publication_name":{"en":"Modern Trends in Obstetrics & Gynecology","ja":"現代産婦人科"},"volume":"Vol.70","number":"No.1","starting_page":"123","ending_page":"128","languages":["jpn"],"identifiers":{"issn":["1882-482X"]},"published_paper_type":"research_institution"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://search.jamas.or.jp/link/ui/2021337801","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390570630076275584/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=390919","label":"url"}],"paper_title":{"en":"婦人科悪性腫瘍に対する妊孕性・機能温存治療の実際","ja":"婦人科悪性腫瘍に対する妊孕性・機能温存治療の実際"},"authors":{"en":[{"name":"Nishimura Masato"}],"ja":[{"name":"西村 正人"}]},"publication_date":"2021-08-25","publication_name":{"en":"Japanese Journal of Imaging Diagnosis","ja":"画像診断"},"volume":"Vol.41","number":"No.10","starting_page":"1060","ending_page":"1066","languages":["jpn"],"identifiers":{"doi":["10.15105/gz.0000002451"],"issn":["0285-0524"]},"published_paper_type":"research_institution"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"http://id.ndl.go.jp/bib/031565319","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1520853834956961920/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=390225","label":"url"}],"paper_title":{"en":"帝王切開時に子宮内にバルーンを留置し二期的子宮摘出(planned delayed hysterectomy)を行った前置癒着胎盤の2例","ja":"帝王切開時に子宮内にバルーンを留置し二期的子宮摘出(planned delayed hysterectomy)を行った前置癒着胎盤の2例"},"authors":{"en":[{"name":"武田 明日香"},{"name":"Kaji Takashi"},{"name":"今泉 絢貴"},{"name":"祖川 英至"},{"name":"Yoshida Atsuko"},{"name":"米谷 直人"},{"name":"Nishimura Masato"},{"name":"Irahara Minoru"},{"name":"Iwasa Takeshi"}],"ja":[{"name":"武田 明日香"},{"name":"加地 剛"},{"name":"今泉 絢貴"},{"name":"祖川 英至"},{"name":"吉田 あつ子"},{"name":"米谷 直人"},{"name":"西村 正人"},{"name":"苛原 稔"},{"name":"岩佐 武"}]},"publication_date":"2021-06-01","publication_name":{"en":"Modern Trends in Obstetrics & Gynecology","ja":"現代産婦人科"},"volume":"Vol.69","number":"No.2","starting_page":"233","ending_page":"238","languages":["jpn"],"identifiers":{"issn":["1882-482X"]},"published_paper_type":"research_institution"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://ci.nii.ac.jp/naid/130007964400/","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390286981364673792/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378955","label":"url"}],"paper_title":{"en":"Mismatch repair deficiency in young patients of reproductive age with endometrial cancer and atypical endometrial hyperplasia","ja":"生殖年齢期に発生した子宮内膜癌・異型内膜増殖症におけるミスマッチ修復蛋白発現に関する検討"},"authors":{"en":[{"name":"Abe Akiko"},{"name":"Kagawa Tomohiro"},{"name":"祖川 英至"},{"name":"Mineda Ayuka"},{"name":"Nishimura Masato"}],"ja":[{"name":"阿部 彰子"},{"name":"香川 智洋"},{"name":"祖川 英至"},{"name":"峯田 あゆか"},{"name":"西村 正人"}]},"description":{"en":"
MPA therapy is widely administered to patients with early-stage endometrial cancer and atypical endometrial hyperplasia (AEH) who desire a fertility-preserving treatment modality. We examined the relationship between MMR protein expression and the effects of MPA therapy, risk of relapse, prognosis, and familial history in 21 patients. We observed MMR deficiency in 7 patients (MLH1: 4, PMS2: 5, MSH2: 2, and MSH6: 2). All patients with lymph node metastasis or who died had MLH1 deficiency. In 13 of 21 patients, we performed MPA therapy for fertility preservation and confirmed MMR deficiency in 2. After the initial treatment, ovarian cancer developed in 2 patients, one of whom had Peutz-Jeghers syndrome. Due to the small sample size of this study, we found no significant association between MMR deficiency and the effects of MPA therapy or the risk of relapse. Many young patients with endometrial tumors may have inherited diseases, although not necessarily with MMR deficiency. Therefore, clinical assessment considering their past history and family history should be performed prior to each treatment. Our findings will serve as a catalyst for future studies with larger sample sizes.
","ja":"妊孕性温存療法希望の早期子宮体癌および異型内膜増殖症症例にMPA療法を行うも不応や再燃症例も経験する.徳島大学産科婦人科で初回治療を行った若年子宮体癌および異型内膜増殖症21症例を対象にミスマッチ修復(mismatch repair;MMR)蛋白発現と,MPA療法の効果,再燃リスク,および予後との関連について検討した.MMR蛋白の発現欠失は7例で認め,MLH1欠失4例,PMS2欠失5例,MSH2欠失2例,MSH6欠失2例であった.リンパ節転移例と再発原病死例はいずれもMLH1欠失例であった.MPA療法施行13例中,MMR欠失を2例で認めたが,いずれもMPA奏効・無病生存例であった.初回治療後,異時性卵巣癌発症を2例に認め,このうちの1例はPeutz-Jeghers症候群であった.本検討では対象例が少なく,MMR蛋白発現とMPA療法の効果および再燃リスクとの間に有意な関連は確認できなかった.しかしMMR欠失を認めなくとも, 遺伝性疾患を背景にもつハイリスク症例もあり,家族歴を考慮した適切な医学的管理が必要であると考えられた.
"},"publication_date":"2020-12","publication_name":{"en":"Journal of Hereditary Tumors","ja":"遺伝性腫瘍"},"volume":"Vol.20","number":"No.3","starting_page":"146","ending_page":"150","languages":["jpn"],"identifiers":{"doi":["10.18976/jsht.20.3_146"],"issn":["2435-6808"]},"published_paper_type":"research_institution"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"http://id.ndl.go.jp/bib/031199545","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1520572359820341376/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=378951","label":"url"}],"paper_title":{"en":"嚢胞状帝王切開瘢痕部が着床部結節から成っていた一例","ja":"嚢胞状帝王切開瘢痕部が着床部結節から成っていた一例"},"authors":{"en":[{"name":"Kagawa Tomohiro"},{"name":"Abe Akiko"},{"name":"Inui Hiroaki"},{"name":"Mineda Ayuka"},{"name":"Nishimura Masato"}],"ja":[{"name":"香川 智洋"},{"name":"阿部 彰子"},{"name":"乾 宏彰"},{"name":"峯田 あゆか"},{"name":"西村 正人"}]},"publication_date":"2020-12-10","publication_name":{"en":"Modern Trends in Obstetrics & Gynecology","ja":"現代産婦人科"},"volume":"Vol.69","number":"No.1","starting_page":"5","ending_page":"9","languages":["jpn"],"identifiers":{"issn":["1882-482X"]},"published_paper_type":"research_institution"}} {"insert":{"type":"published_papers"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=329271","label":"url"}],"paper_title":{"en":"カルチノイド成分を合併した粘液生卵巣癌の1例","ja":"カルチノイド成分を合併した粘液生卵巣癌の1例"},"authors":{"en":[{"name":"門田 友里"},{"name":"Nishimura Masato"},{"name":"炬口 恵理"},{"name":"Kawakita Takako"},{"name":"Abe Akiko"},{"name":"Irahara Minoru"}],"ja":[{"name":"門田 友里"},{"name":"西村 正人"},{"name":"炬口 恵理"},{"name":"河北 貴子"},{"name":"阿部 彰子"},{"name":"苛原 稔"}]},"publication_date":"2016-05-10","publication_name":{"en":"Modern Trends in Obstetrics & Gynecology","ja":"現代産婦人科"},"volume":"Vol.64","number":"No.2","starting_page":"321","ending_page":"325","languages":["jpn"],"identifiers":{"issn":["1882-482X"]},"published_paper_type":"research_institution"}}